


## CLAIMS

I Claim:

- 1) A process for inhibiting NF- $\kappa$ B in a mammalian cell in which NF- $\kappa$ B has been activated by an agency external to said cell which comprises administering to the mammal in whose cells NF- $\kappa$ B has been activated an NF- $\kappa$ B inhibiting amount of a drug represented by the formula:



wherein n is 2-5, m is 0 or 1, R is NH<sub>2</sub>, NHOH, OC<sub>1-3</sub> alkyl, or ~~o~~  
~~phenyl~~, R' is O  
~~phenyl~~, R is o, NH or NOH, R'' is H or OH and pharmaceutically-  
 acceptable acid-addition <sup>salt</sup> ~~salts~~ and acylated phenol derivatives thereof.

- 2) A process according to Claim <sup>14</sup> ~~1~~ in which the external agency activating NF- $\kappa$ B <sup>in</sup> ~~is~~ an inflammatory process <sup>comprising</sup> ~~includes, but is not~~ ~~limited to~~, a cytokine, an activator of protein kinase B, a virus or an oxidant.

HEBVR-5

3) A process according to claim <sup>14</sup><sub>1</sub> in which the external agency activating NF-κB is a drug or radiation administered to the host mammal in a chemotherapeutic process used in the treatment of cancer.

4) A process according to Claim <sup>14</sup><sub>1</sub> in which the administered NF-κB inhibitor is a free-radical scavenger.

5) A therapeutic process according to Claim <sup>14</sup><sub>1</sub> in which the NF-κB inhibitor is N,3,4- trihydroxybenzamide.

6) A therapeutic process according to Claim <sup>14</sup><sub>1</sub> in which the NF-κB inhibitor is N,3,4,5-tetrahydroxybenzamide.

7) A therapeutic process according to Claim <sup>14</sup><sub>1</sub> in which the NF-κB inhibitor is N,3,4-tetrahydroxybenzimidamide.

8) A therapeutic process according to Claim <sup>14</sup><sub>1</sub> in which the NF-κB inhibitor is a ribonucleotide reductase inhibitor.

add a' > add  
F'